CAS: 11027-63-7; ((1S,4Ar,5S,7As)-5-Hydroxy-1-(((2S,3R,4S,5S,6R)-3,4,5-Trihydroxy-6-(Hydroxymethyl)Tetrahydro-2H-Pyran-2-yl)Oxy)-1,4A,5,7A-Tetrahydrocyclopenta[c]Pyran-7-yl)Methyl 4-Hydroxybenzoate
该化合物是化学结构,包括与甘甘甘酮,特别是化合物相连的葡萄糖酶.Agnuside以其潜在的药理特性而著称,包括防炎,抗氧化剂和荷尔蒙调控效应,特别是在生殖健康方面.该化合物主要来自植物Vitex 腺-腺-剖腹产,主要来自该植物,其化学结构的特点是其化学结构,其典型的成分是从沙粒树的果树叶提取的,并经常用于草药配方.从溶液的角度来看,藻素通常在水和有机溶剂中溶解,这有利于提取和融入各种治疗制剂.其安全特征和功效是正在进行的研究的主题,突出了解了解其生物化学相互作用和潜在治疗用途的重要性.
- 英文名称((1S,4Ar,5S,7As)-5-Hydroxy-1-(((2S,3R,4S,5S,6R)-3,4,5-Trihydroxy-6-(Hydroxymethyl)Tetrahydro-2H-Pyran-2-yl)Oxy)-1,4A,5,7A-Tetrahydrocyclopenta[c]Pyran-7-yl)Methyl 4-Hydroxybenzoate
- 中文名称牡荆油
- IUPAC名称((1S,4aR,5S,7aS)-5-hydroxy-1-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-7-yl)methyl 4-hydroxybenzoate
- 其它别名[(1S,4Ar,5S,7As)-1-(Beta-D-Glucopyranosyloxy)-5-Hydroxy-1,4A,5,7A-Tetrahydrocyclopenta[c]Pyran-7-Yl]Methyl 4-Hydroxybenzoate; (-)-Buddlejoside A; Agnoside
- CAS编号11027-63-7
- MFCD编号:MFCD00210471
- EINECS号:683-191-9
- FDA UNII编号:JB24Q0OT9G
- 分子式:C22H26O11分子量:466.44
- 产品CID: 140474
- 产品分类香精与香料 → 天然香料
物理性质
MSDS等安全信息
欧盟法规
ECHA物质C&L通报合成工艺路线路线简述
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2905122000-异丙醇
2905310000-1,2-乙二醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Zhang L, Li X, Zhang H, Huang Z, Zhang N, Zhang L, Xing R, Wang P. Agnuside Alleviates Synovitis and Fibrosis in Knee Osteoarthritis through the Inhibition of HIF-1α and NLRP3 Inflammasome. Mediators Inflamm. 2021 Mar 16;2021:5534614. doi: 10.1155/2021/5534614.
2: Tirpude NV, Sharma A, Bhardwaj N. Agnuside mitigates OVA-LPS induced perturbed lung homeostasis via modulating inflammatory, autophagy, apoptosis- fibrosis response and myeloid lineages in mice model of allergic asthma. Int Immunopharmacol. 2022 May;106:108579. doi: 10.1016/j.intimp.2022.108579. Epub 2022 Feb 7.
160:193-206. doi: 10.1016/j.ejmech.2018.10.009. Epub 2018 Oct 5.
合成参考文献
摘要:S109 | PARCEDC | List of 7074 potential endocrine disrupting compounds (EDCs) by PARC T4.2 | DOI:10.5281/zenodo.10944198
📝 需求与反馈
尽可能描述清楚需求与问题信息
